XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on intellectual property and clinical-stage therapeutic assets. The company is based in Israel and is listed on Nasdaq and the Tel Aviv Stock Exchange, with activity centered on licensed drug development, IP licensing, and ownership of biotechnology assets.
Fiscal year 2024 · change from previous year
Development 2021–2024
Business
Share of revenueLicensing of intellectual property assets, including hCDR1 for autoimmune indications.
Development of psilocybin-based and related psychedelic drug candidates.
Licensed GMP manufacturing infrastructure for psychedelic medicine production.
Research and commercialization of mushroom-derived wellness and therapeutic products.
Partnerships and acquisitions used to expand the therapeutic portfolio.
Customers
XTL sells primarily to pharmaceutical and biotechnology partners that can license, develop, or commercialize its intellectual property and therapeutic programs. Its end markets also include clinical and research stakeholders focused on psychiatric, autoimmune, and other high-unmet-need diseases. Because the company is an asset-light IP and development platform, value is tied to counterparties that can advance assets through trials, manufacturing, and regulatory pathways.
License or acquire therapeutic IP and development rights to advance assets into trials or commercialization.
Work with the company on candidate development, formulation, and scientific validation.
Potential buyers of late-stage or approved assets in psychiatry and related indications.
Provide funding for development, acquisition, and platform expansion.
Strategy
XTL's strategy is to build value around proprietary intellectual property, clinical-stage assets, and manufacturing capabilities rather than a broad commercial product base. The Psyga Bio acquisition adds psychedelic medicine programs and a GMP platform, which broadens the company's development pipeline and potential partnering opportunities. The company also continues to use collaborations and acquisitions to expand into higher-value therapeutic areas.
Clinical-stage candidates and formulations are the main source of future value creation.
Licensing and sublicensing can generate value without requiring large-scale commercialization infrastructure.
External deal flow can quickly add assets, expertise, and scientific optionality.
Geography
XTL is incorporated and operationally anchored in Israel, where its corporate offices and transaction activity are based. The company is listed in the United States and Israel, so its access to capital and investor base spans both markets. Its therapeutic programs and collaborations may also extend into global markets as assets are advanced, licensed, or commercialized.
Risks
The business depends on regulatory acceptance, clinical progress, and successful execution of development programs, all of which are uncertain in early-stage biopharma. It also faces financing and listing-related risk because the company has historically needed access to capital and has had to maintain compliance with exchange rules. As an IP- and asset-driven company, setbacks in trial data, licensing, or acquisition integration could materially affect the value of its portfolio.
- Regulatory and licensing uncertaintyImpact: HighLikelihood: High
Psychedelic medicine remains subject to evolving approvals and controlled-substance rules.
Exposure - Financing and dilution riskImpact: HighLikelihood: High
Development-stage biotech companies often require recurring equity or partner funding.
Exposure: Pipeline advancement and corporate operations
- Clinical development failureImpact: HighLikelihood: Medium
Therapeutic candidates may not demonstrate safety or efficacy in trials.
Exposure: Psilocybin-based programs and other pipeline assets
- Exchange listing complianceImpact: MediumLikelihood: Medium
Failure to meet Nasdaq or other listing requirements can restrict market access.
Exposure: Nasdaq Capital Market listing
Accounting
Judgemental itemsThe Psyga transaction requires allocation of purchase price to acquired assets and liabilities.
Impact: Can create intangible assets, goodwill, and future amortization or impairment
IP and clinical assets may lose value if programs underperform or regulation changes.
Impact: Could generate non-cash charges and affect equity
Private placements and consideration paid in ADSs or warrants can be complex to classify.
Impact: Affects dilution, equity balances, and fair value measurements
Similar listed companies
Publicly listed companies with a comparable business focus.
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Psyence Biomedical Ltd
PBMWW · Pharmaceutical Preparations
Brainstorm Cell Therapeutics Inc.
BCLI · Biological Products, (No Diagnostic Substances)
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
Last updated: 28/09/2026